FDA Determines Regulatory Review Period for XIGRIS Patent Extension

Summary

The US Food and Drug Administration (FDA) has officially confirmed the regulatory review period for XIGRIS, a human biological product, in accordance with federal regulations. This decision was prompted by three patent extension applications submitted to the US Department of Commerce.